top of page
Synterex Blog
Featured Blogs
Search
Faster Isn’t Lighter: What UK Clinical Trial Reforms Mean for Inspection Readiness
UK clinical trial reforms are accelerating timelines—without reducing accountability. Learn how inspection readiness and documentation expectations are evolving.
Jeanette Towles
May 12
Pharma Scale-Back in the United Kingdom: What It Means for UK Pharmaceutical Regulation
In 2025, several major pharmaceutical companies — including MSD (Merck), AstraZeneca, and Eli Lilly — have scaled back or cancelled planned investments in the UK. Decisions have ranged from pausing vaccine-manufacturing expansions to abandoning research center projects.
Jeanette Towles
Oct 2, 2025
bottom of page